{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:20:29Z","timestamp":1787498429495,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    EPN-ZFTA is a rare brain tumor where prognostic factors remain unclear and no effective immunotherapy or chemotherapy is currently available. Therefore, this study investigated its clinicopathological features, evaluated the utility of MTAP and p16 IHC as surrogate markers of\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    alterations, and characterized the immune microenvironment of EPN-ZFTA. Thirty surgically removed brain tumors, including 10 EPN-ZFTA, were subjected to IHC. MLPA was performed for\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    HD in 20 ependymal tumors, including EPN-ZFTA. The 5-years OS and PFS of EPN-ZFTA were 90% and 60%, respectively.\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    HD was detected in two cases of EPN-ZFTA; these cases were immunohistochemically negative for both MTAP and p16 and recurred earlier after surgery. As for the immune microenvironment of EPN-ZFTA, B7-H3, but not PD-L1, was positive in all cases of EPN-ZFTA; Iba-1-positive or CD204-positive macrophages were large, while infiltrating lymphocytes were small, in number in EPN-ZFTA. Collectively, these results indicate the potential of MTAP and p16 IHC as useful surrogate markers of\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    HD in EPN-ZFTA, and tumor-associated macrophages, including the M2 type, may contribute to its immune microenvironment. Furthermore, the expression of B7-H3 in EPN-ZFTA may indicate the usefulness of B7-H3 as a target of immune checkpoint chemotherapy for EPN-ZFTA via B7-H3 pathway.\n                  <\/jats:p>","DOI":"10.1007\/s10014-023-00464-7","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T23:27:41Z","timestamp":1686871661000},"page":"163-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment"],"prefix":"10.1007","volume":"40","author":[{"given":"Naohito","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumihito","family":"Nobusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-9391","authenticated-orcid":false,"given":"Atsushi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"464_CR1","first-page":"112","volume-title":"WHO classification of Tumours of the central nervous system","author":"DW Ellison","year":"2016","unstructured":"Ellison DW, Korshunov A, Witt H (2016) Ependymoma, RELA fusion-positive. In: Louis DN, Ohgaki H, Wiestler OD (eds) WHO classification of Tumours of the central nervous system. IARC Press, Lyon, pp 112\u2013114"},{"key":"464_CR2","first-page":"164","volume-title":"WHO classification of tumours of the central nervous system","author":"KW Pajtler","year":"2021","unstructured":"Pajtler KW, Pietsch T, Aldape KD et al (2021) Supratentorial ependymoma, ZFTA fusion-positive. In: Cree IA, Lokuhetty D, Peferoen LAN (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, pp 164\u2013166"},{"key":"464_CR3","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/neuonc\/noy118","volume":"20","author":"H Witt","year":"2018","unstructured":"Witt H, Gramatzki D, Hentschel B et al (2018) DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro Oncol 20:1616\u20131624","journal-title":"Neuro Oncol"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/neuonc\/now025","volume":"18","author":"D Figarella-Branger","year":"2016","unstructured":"Figarella-Branger D, Lechapt-Zalcman E, Tabouret E et al (2016) Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro Oncol 18:919\u2013927","journal-title":"Neuro Oncol"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature13109","volume":"506","author":"M Parker","year":"2014","unstructured":"Parker M, Mohankumar KM, Punchihewa C et al (2014) C11orf95-RELA fusions drive oncogenic NF-\u03baB signalling in ependymoma. Nature 506:451\u2013455","journal-title":"Nature"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10014-019-00338-x","volume":"36","author":"A Sasaki","year":"2019","unstructured":"Sasaki A, Hirato J, Hirose T et al (2019) Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome. Brain Tumor Pathol 36:92\u2013101","journal-title":"Brain Tumor Pathol"},{"key":"464_CR7","first-page":"107","volume":"37","author":"N Hashimoto","year":"2020","unstructured":"Hashimoto N, Ishizawa K, Ikota H et al (2020) Usefulness of immunohistochemistry and FISH analysis in the pathological diagnosis of ependymoma, RELA fusion-positive. Jpn J Diagn Pathol 37:107\u2013114","journal-title":"Jpn J Diagn Pathol"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","volume":"133","author":"KW Pajtler","year":"2017","unstructured":"Pajtler KW, Mack SC, Ramaswamy V et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133:5\u201312","journal-title":"Acta Neuropathol"},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/neup.12014","volume":"33","author":"S Purkait","year":"2013","unstructured":"Purkait S, Jha P, Sharma MC et al (2013) CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology 33:405\u2013412","journal-title":"Neuropathology"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00401-020-02169-z","volume":"140","author":"ST Junger","year":"2020","unstructured":"Junger ST, Andreiuolo F, Mynarek M et al (2020) CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathol 140:405\u2013407","journal-title":"Acta Neuropathol"},{"key":"464_CR11","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00381-020-04655-x","volume":"36","author":"ST Junger","year":"2020","unstructured":"Junger ST, Andreiuolo F, Mynarek M et al (2020) Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome. Child\u2019s Nervous Syst 36:2693\u20132700","journal-title":"Child\u2019s Nervous Syst"},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41379-020-00701-w","volume":"34","author":"K Satomi","year":"2021","unstructured":"Satomi K, Ohno M, Matsushita Y et al (2021) Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol 34:688\u2013700","journal-title":"Mod Pathol"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-018-2278-x","volume":"68","author":"SJ Nam","year":"2019","unstructured":"Nam SJ, Kim YH, Park JE et al (2019) Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. Cancer Immunol Immunother 68:305\u2013318","journal-title":"Cancer Immunol Immunother"},{"key":"464_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/1078-0432.CCR-11-0880","volume":"18","author":"D Lemke","year":"2012","unstructured":"Lemke D, Pfenning PN, Sahm F et al (2012) Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res 18:105\u2013117","journal-title":"Clin Cancer Res"},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/nan.12428","volume":"44","author":"MD Sorensen","year":"2018","unstructured":"Sorensen MD, Dahlrot RH, Boldt HB et al (2018) Tumour-associated microglia\/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Neuropathol Appl Neurobiol 44:185\u2013206","journal-title":"Neuropathol Appl Neurobiol"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11060-019-03138-7","volume":"143","author":"N Matsumura","year":"2019","unstructured":"Matsumura N, Nobusawa S, Ito J et al (2019) Multiplex ligation-dependent probe amplification analysis is useful for detecting a copy number gain of the FGFR1 tyrosine kinase domain in dysembryoplastic neuroepithelial tumors. J Neurooncol 143:27\u201333","journal-title":"J Neurooncol"},{"key":"464_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/PDM.0b013e3182595516","volume":"21","author":"C Homig-Holzel","year":"2012","unstructured":"Homig-Holzel C, Savola S (2012) Multiplex Ligation-dependent Probe Amplification (MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol 21:189\u2013206","journal-title":"Diagn Mol Pathol"},{"key":"464_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1097\/PAS.0000000000001520","volume":"44","author":"S Nobusawa","year":"2020","unstructured":"Nobusawa S, Nakata S, Nakano Y et al (2020) CNS low-grade diffusely infiltrative tumors with INI1 deficiency, possessing a high propensity to progress to secondary INI1-deficient Rhabdoid Tumors. Am J Surg Pathol 44:1459\u20131468","journal-title":"Am J Surg Pathol"},{"key":"464_CR19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/PAS.0000000000001669","volume":"45","author":"F Zhao","year":"2021","unstructured":"Zhao F, Wu T, Wang L et al (2021) Survival and prognostic factors of adult intracranial ependymoma: a single-institutional analysis of 236 patients. Am J Surg Pathol 45:979\u2013987","journal-title":"Am J Surg Pathol"},{"key":"464_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAS.0000000000000979","volume":"43","author":"M Gessi","year":"2019","unstructured":"Gessi M, Giagnacovo M, Modena P et al (2019) Role of immunohistochemistry in the identification of supratentorial C11orf95-RELA fused ependymoma in routine neuropathology. Am J Surg Pathol 43:56\u201363","journal-title":"Am J Surg Pathol"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Witt H, Sill M et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728\u2013743","journal-title":"Cancer Cell"},{"key":"464_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10014-021-00417-y","volume":"39","author":"KY Lim","year":"2022","unstructured":"Lim KY, Lee K, Shim Y et al (2022) Molecular subtyping of ependymoma and prognostic impact of Ki-67. Brain Tumor Pathol 39:1\u201313","journal-title":"Brain Tumor Pathol"},{"key":"464_CR23","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.3390\/cancers13246218","volume":"13","author":"T Larrew","year":"2021","unstructured":"Larrew T, Saway BF, Lowe SR et al (2021) Molecular classification and therapeutic targets in eendymoma. Cancers 13:6218. https:\/\/doi.org\/10.3390\/cancers13246218","journal-title":"Cancers"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"JP Thakkar","year":"2014","unstructured":"Thakkar JP, Dolecek TA, Ostrom QT et al (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 23:1985\u20131996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"464_CR25","first-page":"2108","volume":"9","author":"PB Illei","year":"2003","unstructured":"Illei PB, Rusch VW, Zakowski MF et al (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9:2108\u20132113","journal-title":"Clin Cancer Res"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.1073\/pnas.93.12.6203","volume":"93","author":"T Nobori","year":"1996","unstructured":"Nobori T, Takabayashi K, Tran P et al (1996) Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci USA 93:6203\u20136208","journal-title":"Proc Natl Acad Sci USA"},{"key":"464_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005072-199802000-00003","volume":"57","author":"KL Burns","year":"1998","unstructured":"Burns KL, Ueki K, Jhung SL et al (1998) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57:122\u2013130","journal-title":"J Neuropathol Exp Neurol"},{"key":"464_CR28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/neuonc\/noaa257","volume":"23","author":"M Massimino","year":"2021","unstructured":"Massimino M, Barretta F, Modena P et al (2021) Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro Oncol 23:848\u2013857","journal-title":"Neuro Oncol"},{"key":"464_CR29","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/cncr.20075","volume":"100","author":"A Korshunov","year":"2004","unstructured":"Korshunov A, Golanov A, Sycheva R et al (2004) The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 100:1230\u20131237","journal-title":"Cancer"},{"key":"464_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.4132\/jptm.2017.08.10","volume":"51","author":"S Kim","year":"2017","unstructured":"Kim S, Lee Y, Kim S et al (2017) Aggressive supratentorial ependymoma, RELA fusion positive with extracranial metastasis: a case report. J Pathol Transl Med 51:588\u2013593","journal-title":"J Pathol Transl Med"},{"key":"464_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s40478-020-01080-8","volume":"8","author":"M Takadera","year":"2020","unstructured":"Takadera M, Satomi K, Szulzewsky F et al (2020) Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes. Acta Neuropathol Commun 8:203","journal-title":"Acta Neuropathol Commun"},{"key":"464_CR32","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","volume":"35","author":"R Buttner","year":"2017","unstructured":"Buttner R, Gosney JR, Skov BG et al (2017) Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 35:3867\u20133876","journal-title":"J Clin Oncol"},{"issue":"5","key":"464_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26960","volume":"65","author":"DA Witt","year":"2018","unstructured":"Witt DA, Donson AM, Amani V et al (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: implications for PD-1-targeted therapy. Pediatr Blood Cancer 65(5):e26960","journal-title":"Pediatr Blood Cancer"},{"key":"464_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS et al (2001) B7\u2013H3: a constimulatory molecule for T cell activation and IFN-\u03b3 production. Nat Immunol 2:269\u2013274","journal-title":"Nat Immunol"},{"key":"464_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12521","volume":"276","author":"M Janakiram","year":"2017","unstructured":"Janakiram M, Shah UA, Liu W et al (2017) The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x and B7\u2013H3. Immunol Rev 276:26\u201339","journal-title":"Immunol Rev"},{"key":"464_CR36","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","volume":"172","author":"P Steinberger","year":"2004","unstructured":"Steinberger P, Majdic O, Derdak SV et al (2004) Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig like domains. J Immunol 172:2352\u20132359","journal-title":"J Immunol"},{"key":"464_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/bjc.2014.286","volume":"111","author":"J Kraan","year":"2014","unstructured":"Kraan J, Broek P, Verhoef C et al (2014) Endothelial CD276 (B7\u2013H3) expression is increased in human malignancies and distinguishes between normal and tumor-derived circulating endothelial cells. Br J Cancer 111:149\u2013156","journal-title":"Br J Cancer"},{"key":"464_CR38","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","volume":"67","author":"TJ Roth","year":"2007","unstructured":"Roth TJ, Sheinin Y, Lohse CM et al (2007) B7\u2013H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67:7893\u20137900","journal-title":"Cancer Res"},{"key":"464_CR39","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12094-021-02762-y","volume":"24","author":"S Li","year":"2022","unstructured":"Li S, Poolen GC, Vliet LC et al (2022) Pediatric medulloblastoma express immune checkpoint B7\u2013H3. Clin Transl Oncol 24:1204\u20131208","journal-title":"Clin Transl Oncol"},{"key":"464_CR40","doi-asserted-by":"publisher","first-page":"E4055","DOI":"10.1073\/pnas.1501967112","volume":"112","author":"D Kozono","year":"2015","unstructured":"Kozono D, Li J, Nitta M et al (2015) Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc Natl Acad Sci USA 112:E4055-4064","journal-title":"Proc Natl Acad Sci USA"},{"key":"464_CR41","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/eji.200839028","volume":"39","author":"J Leitner","year":"2009","unstructured":"Leitner J, Klauser C, Pickl WF et al (2009) B7\u2013H3 is a potent inhibitor of human T-cell activation: no evidence for B7\u2013H3 ant TREML2 interaction. Eur J Immunol 39:1754\u20131764","journal-title":"Eur J Immunol"},{"key":"464_CR42","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41374-019-0238-5","volume":"99","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang J, Marzese DM et al (2019) B7\u2013H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma. Lab Invest 99:1117\u20131129","journal-title":"Lab Invest"},{"key":"464_CR43","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/neuonc\/nox081","volume":"19","author":"C Zhu","year":"2017","unstructured":"Zhu C, Kros JM, Cheng C et al (2017) The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. Neuro Oncol 19:1435\u20131446","journal-title":"Neuro Oncol"},{"key":"464_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4049\/jimmunol.1000413","volume":"185","author":"G Solinas","year":"2010","unstructured":"Solinas G, Schiarea S, Liguori M et al (2010) Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 185:642\u2013652","journal-title":"J Immunol"},{"key":"464_CR45","first-page":"2093","volume":"28","author":"GT Burnett","year":"2008","unstructured":"Burnett GT, Weathersby DC, Taylor TE et al (2008) Regulation of inflammation- and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages. Anticancer Res 28:2093\u20132100","journal-title":"Anticancer Res"},{"key":"464_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677\u2013686","journal-title":"Trends Immunol"},{"key":"464_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"ARP Antunes","year":"2021","unstructured":"Antunes ARP, Scheyltjens I, Lodi F et al (2021) Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neurosci 24:595\u2013610","journal-title":"Nature Neurosci"},{"key":"464_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bpa.12690","volume":"29","author":"PS Zeiner","year":"2019","unstructured":"Zeiner PS, Preusse C, Golebiewska A et al (2019) Distribution and prognostic impact of microglia\/macrophage subpopulations in gliomas. Brain Pathol 29:513\u2013529","journal-title":"Brain Pathol"},{"key":"464_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2990.2004.00556.x","volume":"30","author":"A Sasaki","year":"2004","unstructured":"Sasaki A, Yamaguchi H, Horikoshi Y et al (2004) Expression of glucose transporter 5 by microglia in human gliomas. Neuropathol Appl Neurobiol 30:447\u2013455","journal-title":"Neuropathol Appl Neurobiol"},{"key":"464_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","volume":"10","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Murakami R, Hamanishi J et al (2022) B7\u2013H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res 10:56\u201369","journal-title":"Cancer Immunol Res"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-023-00464-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-023-00464-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-023-00464-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:31:54Z","timestamp":1702600314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-023-00464-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s10014-023-00464-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2636228\/v1","asserted-by":"object"}]},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study that involves human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval consent to participate"}},{"value":"The concent for use or publication of data was obtained from all patients involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}